{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:34:46Z","timestamp":1769171686866,"version":"3.49.0"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.3661","type":"journal-article","created":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T10:57:27Z","timestamp":1427885847000},"page":"823-826","source":"Crossref","is-referenced-by-count":31,"title":["Minimal Change Nephrotic Syndrome Associated with Gefitinib and a Successful Switch to Erlotinib"],"prefix":"10.2169","volume":"54","author":[{"given":"Keisuke","family":"Maruyama","sequence":"first","affiliation":[{"name":"Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Chinda","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuki","family":"Kuroshima","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Kabara","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Fujino","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Respiratory Center, Asahikawa Medical University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Ohsaki","sequence":"additional","affiliation":[{"name":"Respiratory Center, Asahikawa Medical University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayoi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"GeneticLab Co., Ltd., Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Hasebe","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Glassock RJ. Secondary minimal change disease. Nephrol Dial Transplant 18 (Suppl 6): vi52-vi58, 2003.","DOI":"10.1093\/ndt\/gfg1060"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kumasaka R, Nakamura N, Shirato K, et al. Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy. J Clin Oncol 22: 2504-2505, 2004.","DOI":"10.1200\/JCO.2004.09.064"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Dabbs DJ, Striker LM, Mignon F, Striker G. Glomerular lesions in lymphomas and leukemias. Am J Med 80: 63-70, 1986.","DOI":"10.1016\/0002-9343(86)90049-5"},{"key":"4","unstructured":"4. Yamagata T, Akamatsu K, Kuroda M, et al. Squamous cell lung cancer with minimal-change nephrotic syndrome. Nihon Kokyuki Gakkai Zasshi 36: 1032-1037, 1998 (in Japanese, Abstract in English)."},{"key":"5","unstructured":"5. Miyajima S, Taguchi Y, Tanaka E, et al. A case of pulmonary adenocarcinoma accompanied by minimal change nephrotic syndrome, antiphospholipid syndrome and warm-type autoimmune hemolytic anemia. Nihon Kokyuki Gakkai Zasshi 44: 631-635, 2006 (in Japanese, Abstract in English)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ohara G, Satoh H, Kurishima K, et al. Paraneoplastic nephrotic syndrome in patients with lung cancer. Intern Med 48: 1817-1820, 2009.","DOI":"10.2169\/internalmedicine.48.2089"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Black DA, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br Med J 22: 421-426, 1970.","DOI":"10.1136\/bmj.3.5720.421"},{"key":"8","unstructured":"8. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.","DOI":"10.1056\/NEJMoa0810699"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29: 2866-2874, 2011.","DOI":"10.1200\/JCO.2010.33.4235"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 361: 137-139, 2003.","DOI":"10.1016\/S0140-6736(03)12190-3"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Cersosimo RJ. Gefitinib: an adverse effects profile. Expert Opin Drug Saf 5: 469-479, 2006.","DOI":"10.1517\/14740338.5.3.469"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wan HL, Yao NS. Acute renal failure associated with gefitinib therapy. Lung 184: 249-250, 2006.","DOI":"10.1007\/s00408-005-2581-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Masutani K, Fujisaki K, Maeda H, et al. Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib. Clin Exp Nephrol 12: 398-402, 2008.","DOI":"10.1007\/s10157-008-0066-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yoshida T, Yamada K, Azuma K, et al. Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis. Med Oncol 30: 349, 2013.","DOI":"10.1007\/s12032-012-0349-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kurita N, Mise N, Fujii A, et al. Crescentic glomerulonephritis in a patient with advanced lung cancer during erlotinib therapy. Nephrol Dial Transplant Plus 2: 513-514, 2009.","DOI":"10.1093\/ndtplus\/sfp134"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Zhang MZ, Wang Y, Paueksakon P, Harris RC. Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. Diabetes 63: 2063-2072, 2014.","DOI":"10.2337\/db13-1279"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Mihovilovic K, Ljubanovic D, Knotek M. Safe administration of celecoxib to a patient with repeated episodes of nephrotic syndrome induced by NSAIDs. Clin Drug Investig 31: 351-355, 2011.","DOI":"10.1007\/BF03256934"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T04:22:28Z","timestamp":1498191748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/7\/54_54.3661\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.3661","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}